

ASX Announcement

9 July 2024

Cleansing notice under section 708A(5)(e) of the Corporations Act

This notice is being given by Recce Pharmaceuticals Ltd (**ASX:RCE**) (**Recce** or **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company today issued 17,777,788 fully paid ordinary shares (**New Shares**) at an issue price of \$0.45 per New Share to institutional and sophisticated investors under the placement announced on 2 July 2024.

For the purposes of section 708A(6) of the Corporations Act, the Company advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

In accordance with paragraph 7(f) of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*, this notice also serves as a cleansing notice for the securities purchase plan of Recce.

This announcement has been approved for release by the Board.

For more information, please contact:

Maggie Niewidok
Company Secretary



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 T +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA